BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Borsa Italiana 21:04:59 20/05/2024 BST | ||
| 3.44 EUR | 0.00% |
|
| Current month | +0.29% | ||
| 1 month | +51.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 3.44 | -1.71% |
| 17/05/24 | 3.5 | -1.13% |
| 16/05/24 | 3.54 | -0.56% |
| 15/05/24 | 3.56 | -4.56% |
| 14/05/24 | 3.73 | +0.27% |
Real-time Borsa Italiana
Last update May 20, 2024 at 09:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S34845 | |
| ISIN | DE000SW8KVN2 |
| Date issued | 08/04/2024 |
| Strike | 9,161 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.88 € |
|---|---|
| Lowest since issue | 1.75 € |
| Spread | 0.13 € |
| Spread % | 3.69% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- S34845 Certificat
